Geron Corporation ( GERN ) saw a big move last session, as the company's shares fell by over 5% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the recent trend for GERN as the stock is now up over 59% in the past one-month time frame.
This biopharmaceutical company has seen a flat track record when it comes to current year estimate revisions over the past few weeks. There has been no upward or downward revision and the consensus for earnings hasn't been in a trend either. This recent price action is discouraging, so make sure to keep a close watch of this firm in the near future, and especially on earnings estimates following the recent slump.
GERN currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.
Investors interested in the Med-Biomed/Gene industry may consider better-ranked stocks like Agenus Inc. ( AGEN ), Alexion Pharmaceuticals, Inc. ( ALXN ) and AVEO Pharmaceuticals, Inc. ( AVEO ). All these stocks carry a Zacks Rank #2 (Buy).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.